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Kidneys are highly aerobic organs that are critically dependent on the normal functioning of mitochondria.
Genetic variations disruptingmitochondrial function are associated withmultifactorial disorders including
kidney disease. This study sequenced the entire mitochondrial genome in a renal transplant cohort of 64
individuals, using next-generation sequencing, to evaluate the association of genetic variants with IgA
nephropathy and end-stage renal disease (ESRD, n5100).
M
itochondrial DNAwas amplified in two fragments using long-range PCR and sequenced on an Illumina
GenomeAnalyzer II platform using TruSeq, with variants confirmed using bidirectional Sanger sequen-
cing. A total of 427 differences from the mitochondrial DNA reference sequence were identified, of
which 113 had a minor allele frequency .5% in this population. Five common SNPs revealed evidence of
significant association (P # 1024) with ESRD where patients had a primary diagnosis of IgA nephropathy.
Sixty-four percent of common SNPs were present in individuals with IgA nephropathy.
There is an excess burden of common mtDNA SNPs in renal transplant recipients with IgA nephropathy
compared with individuals who have no evidence of renal disease. Genetic risk profiles may assist clinical
stratification of renal transplant patients, and we have validated a cost-effective approach to genotype larger,
carefully phenotyped cohorts.
Glomerulonephritis (GN) is themost common primary renal diagnosis in patients receiving renal replacement
therapy (RRT) in the UK, accounting for 18.8% of the prevalent end-stage renal disease (ESRD) cohort in 20121.
Kidneys are highly aerobic organs, and are critically dependent on mitochondrial activity. Mitochondria possess
DNA that is discrete from the nuclear genome in the form of a circular, double-strandedmolecule (mtDNA). The
16,569 base pair mitochondrial genome encodes 13 respiratory chain proteins, two rRNAs, and 22 tRNAs2.
Genetic variations disrupting mitochondrial function are associated with increased molecular stress and multi-
factorial disorders including kidney disease3–11.
Genetic variation in mtDNA may be inherited or acquired (termed somatic mutations) throughout life.
MtDNA is particularly susceptible to acquiring somatic mutations as they both generate and respond to poten-
tially mutagenic reactive oxygen species (ROS) and mtDNA lacks the protective and efficient repair systems
associated with nuclear DNA. Mutations in mtDNA range from single base changes to large scale deletions. The
4977 bp ‘‘common deletion’’ has been associated with a number of disorders, including the renal diseases of focal
segmental glomerulosclerosis (FSGS) and immunoglobin-A nephropathy (IgA nephropathy)12, the most com-
mon form of glomerulonephritis in the UK. Another frequently studied mutation is the 3243A.G single base
change which is associated with MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke like
episodes) and FSGS13,14. MELAS can have renal involvement in the form of FSGS, but is uncommon in White
European populations15.
This project sought to comprehensively investigate mitochondrial genetic variants for association with IgA
nephropathy and ESRD, using a next-generation sequencing approach for the entire mitochondrial genome.
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Results
There was an average of 1 million reads per DNA sample (range
36,492–3,327,485 reads) with 98% of 71 base reads aligned to the
mitochondrial genome. There was.99.9% coverage of eachmtDNA
base with mapping quality score.40 and average coverage depth of
11,092x (Supplementary Table 1).
A total of 427 differences from the reference sequence were iden-
tified (Figure 1, Supplementary Figure 2, Supplementary Table 2), of
which 55 had a minor allele frequency (MAF) of zero, leaving 372
SNPs in this population; 113 SNPs had a MAF greater than 5%. Five
common SNPs revealed evidence of significant association with
ESRD where patients had a primary diagnosis of IgA nephropathy
(Table 1; 6419A.C, P53.67 3 1026; 199T.C, P53.00 3 1024;
150C.T, P54.00 3 1024; 8251G.A, P54.00 3 1024; 16565C.G,
P59.00 3 1024). The association of 6419A.C was maintained fol-
lowing permutation testing (n5100,000 permutations) based on 427
variants with resultant P50.01. Ten SNPs with MAF less than 5%
and 65 common SNPs were present only in the case group of indi-
viduals with IgA nephropathy. Strong linkage disequilibriumwas not
observed (Figure 2).
Discussion
This study of 32 cases and 32 controls provides ,60% power to
identify a risk variant with an odds ratio of 2.0 at a 30% minor allele
frequency. The relatively small number of persons assessed in this
study means it is not sufficiently powered to identify significant
association with rare mtDNA variants, nor risk variants with small
effect sizes, however we have identified mitochondrial SNPs that are
significantly associated with IgA nephropathy, confirmed significant
association following correction for multiple testing, and shown
there is an excess burden of common mtDNA variants in the case
group with 75 SNPs present only in individuals with IgA nephro-
Figure 1 | Vector NTI image of all SNPs on mitochondrial genome. All genes are named in black text, with protein coding genes indicated by orange
arrows and ribosomal RNA genes indicated by green arrows. Top five most significantly associated SNPs shown labelled in dark red. Other significant
SNPs represented by dark red lines, common SNPs by blue lines, and rare variants by black lines.
www.nature.com/scientificreports
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pathy. Additionally, we have developed an efficient, cost-effective
protocol for comprehensive analysis of the mtDNA sequence with
extensive technical validation of the experimental approach. SNPs in
the mitochondrial genome are often excluded from genome-wide
association studies so this study provides complementary informa-
tion to ongoing genetic epidemiology research of autosomes. We
have provided frequency data, the exact location of all identified
SNPs, and details of the relationship between common SNPs.
From the 113 SNPs observed with a minor allele frequency greater
than 5%, five common SNPs showed significant association with IgA
nephropathy where P # 1024. Association of 6419A.C with IgA
nephropathy wasmaintained following permutation testing to adjust
for multiple testing bias. This transversion SNP 6419A.C is rela-
tively common with aminor allele frequency of 22% and is located in
codon 172 of themitochondrial DNA encoded cytochrome c oxidase
subunit 1 (MT-CO1) gene, creating an amino acid change from lysine
to asparagine. The functional result of this change in amino acid is
unknown. Cytochrome c oxidase, a component of the respiratory
chain, catalyses the reduction of oxygen to water; CO1 is the catalytic
subunit of the enzyme. MT-CO1 expression has been shown to be
increased in patients with chronic kidney disease and hemodialysis16.
This increase may be part of a compensatory response to the
increased ROS generation in the uremic state, as ROS can inhibit
respiratory chain enzyme activity17.
Regions of the mitochondrial genome demonstrate homology
with human autosomes in the nuclear genome. It is possible that
‘SNPs’ identified in this study are derived from amplified regions
not in the mitochondrial genome, but sequence alignment and
SNP calling was performed (automated by the software and visual
confirmation of results by two researchers) blinded to case versus
control status so should have affected case and control samples
equally. Off-target and duplicate reads were excluded from analysis;
the coverage depth and quality of alignment to the mitochondrial
genome was excellent, providing confidence in the results of this
study. Additionally, we explicitly enriched for mtDNA based on long
range PCR, called SNPs in duplicate for 32 samples that were inde-
pendently amplified, and validated SNPs (.10% heteroplasmy)
using Sanger sequencing with PCR primers designed to specifically
amplifymtDNA and prevent co-amplification of nuclear DNAbased
on the human genome reference sequence GRCh37.
This study identified a number of novel variants significantly
associated with IgA nephropathy using a case-control approach.
Additionally, we have genotyped an independent cohort of 50 renal
transplant recipients without IgA nephropathy, compared to 50 age
and gender matched controls with no evidence of kidney disease,
which supports genetic association with IgA nephropathy specif-
ically. Ideally, future studies will be conducted using next generation
sequencing to evaluate a larger cohort of patients with ESRD attrib-
uted to IgA nephropathy compared to healthy controls, utilising
multi-centre collaborations.
Survival analysis was not performed as this study is not optimally
designed to assess patient or graft survival. However, seventeen
patients returned to dialysis following graft failure in this cohort;
48 SNPs, all with MAF.5%, were present only in those individuals
whose kidney transplant failed.
Mitochondria also depend on a number of nuclear genome pro-
ducts for their function, and further study in this area might examine
both mtDNA and nuclear genes associated with mitochondrial dis-
orders. For example, a next generation sequencing, clinically targeted
assay has been developed using RainDance and Illumina approaches
to examine the mitochondrial genome and 108 selected nuclear
genes implicated in mitochondrial disease18. Of note, mtDNA
sequences can also be extracted from non-targeted mtDNA amp-
lification, such as exome sequencing data, which provides substantial
opportunities for further mtDNA research19–21.
This study utilised a cost-efficient, high throughput approach to
identify novel genetic variants in mtDNA associated with IgA neph-
ropathy. Additionally, we revealed an excess burden of mtDNA var-
iations in renal transplant recipients with ESRD, secondary to IgA
nephropathy, compared with individuals who have no evidence of
Table 1 | SNPs demonstrating significant association with IgA nephropathy. HV2, Hypervariable segment 2; CO1, Cytochrome c oxidase
subunit I; CO2, Cytochrome c oxidase subunit II; MAF, minor allele frequency
SNP base position Location MAF (%) Alleles Case frequency (%) Control frequency (%)
P value for IgA nephropathy
(n532)
P value for ESRD
(n5100)
150 MT-HV2 14 C:T 25.0 3.1 4.003 1024 .0.05
199 MT-HV2 9 T:C 18.8 0 3.003 1024 .0.05
6419 MT-CO1 22 A:C 40.7 3.7 3.673 1026 .0.05
8251 MT-CO2 14 G:A 25.0 3.1 4.003 1024 .0.05
16565 Control
region
17 C:G 27.6 2.4 9.003 1024 .0.05
Figure 2 | Linkage disequilibrium plots for confidence intervals onD’ and r2 respectively where all SNPs had aminimumminor allele frequency of 5%.
www.nature.com/scientificreports
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renal disease. Building up genetic risk profiles may assist risk strati-
fication of renal transplant patients, and aid the development of
treatment strategies. These results are encouraging, confirming that
further research is warranted in larger, carefully phenotyped cohorts.
Methods
Participants. The Regional Nephrology Unit at Belfast City Hospital is the only
centre providing kidney transplant procedures in Northern Ireland. This single-
centre site facilitates comprehensive analyses since DNA is available for all transplant
recipient-kidney donor pairs in first deceased donor kidney transplants since 1986
with extensive prospective clinical follow-up22,23. DNA was extracted from blood
samples obtained prior to kidney transplantation using the salting out method23. All
experiments were performed in accordance with relevant guidelines and regulations.
This study had full ethical approval from the Office of Research Ethics Committees,
Northern Ireland (ORECNI reference: 08/NIR03/79). Sixty-four individuals were
selected for mtDNA next-generation sequencing (NGS) of the entire mitochondrial
genome. This consisted of transplant recipients (cases, n532) with age and gender
matched donors (controls, n532). All transplant recipients had ESRD secondary to
primary IgA nephropathy proven by immunofluorescence staining of renal biopsies.
A further 50 renal transplant recipients with ESRD, but without IgA nephropathy
(cases), were compared to 50 age and gender matched kidney donor (control)
individuals with no evidence of kidney disease from Belfast.
Next-generation sequencing. The mtDNA of all DNA samples were individually
amplified using long-range PCR (Qiagen, Crawley, UK LongRange PCR Kit), in two
overlapping fragments (fragment 1 5 9,289 bp; fragment 2 5 7,626 bp) [15].
Agarose gel electrophoresis (0.7%) was used to confirm the presence of PCR product.
PicoGreen quantitation (Life Technologies, Warrington, UK) was employed to
quantitate PCR products for fragments 1 & 2, which were then pooled in equimolar
amounts for each individual and barcoded for downstream analysis. Barcoding each
sample facilitates inexpensive pooling of DNA to generate sequence data, which can
be later extracted to analyse each individual separately using bioinformatic tools.
Samples were prepared using the Illumina TruSeq NGS protocol according to
manufacturer’s instructions, enriched DNA was quantitated using Qubit (Life
Technologies) and sequencing was performed using an Illumina Genome Analyzer II
platform. DNA from the 32 individuals in the case group was separately prepared and
sequenced in duplicate for optimisation and validation of the technique; once in a 32
sample pool, and again using two pools comprising 16 samples each. Targeted next
generation sequencing data was analysed for SNPs associated with IgA nephropathy
in an independent case-control cohort for ESRD.
Validation by Sanger sequencing. Four samples, two renal transplant recipients and
two kidney donors, underwent comprehensive Sanger sequencing of the entire
mitochondrial genome to validate the NGS results derived from Illumina. Sixty-two
internal sequencing primers were employed alongside nine overlapping primer pairs
to amplify adequately sized fragments for Sanger sequencing24,25. Bidirectional
sequencing was performed on an ABI 3730 Genetic Analyser (Life Technologies)
Analysis. Initial alignment and quality control was performed using Partek Flow
version 2.2.3, 64 bit architecture for pair-end FASTQ files (Partek Inc, Missouri,
USA). Post-alignment quality control and analysis (QC/QA)was performed in Partek
Genomics Suite version 6.6 (Partek Inc), in order to visualise the quality of aligned
reads. Coverage across the mitochondrial genome was visualised using Partek
Genomics Suite (Supplementary Figure 1). Partek Genomics Suite was used to call
SNPs against the revised Cambridge Reference Sequence for mtDNA (rCRS,
NC_012920), and an allele percentage test against the rCRS was also undertaken to
evaluate heteroplasmy. Sequence data was analysed for quality control and the
presence of SNPs blinded to case and control status. Concordance was analysed
between duplicate samples. Case-control analysis was performed using the open
source software Haploview26. Linkage disequilibrium plots for the IgA nephropathy
cohort were generated using D’ and r2 measures in Haploview.
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